The Director-General of the National Agency for the Control of AIDS, Temitope Ilori, has clarified that the newly introduced long-acting HIV prevention injection, Lenacapavir (LenPrEP), is not recommended for use among pregnant women. “Even though LenPrEP is considered very safe based on global studies, it is not recommended for pregnant women. He noted that Lenacapavir would complement, not replace, existing HIV prevention methods such as oral pre-exposure prophylaxis. Lenacapavir, a long-acting injectable developed by Gilead Sciences, has recently gained global attention as a potential breakthrough in HIV prevention. For now, health authorities maintain that Lenacapavir represents an important addition to the country’s HIV prevention toolkit—but not a standalone solution.

Source: Punch March 23, 2026 12:10 UTC